NTRK fusion genes are valuable diagnostic and prognostic markers.
Cancers 2021, 13(8), 1932
High LC3 protein expression shows a certain prognostic value in CRC patients. LC3, the MSI status, and KRAS
mutations must be considered when selecting an adjuvant therapy for CRC. The detection of these indexes is of
great significance to identify high-risk patients who would benefit from autophagy-related anticancer drugs or help
to explore more effective treatment options for patients who are resistant to conventional chemotherapy or relapse.
Journal of Cancer. 2021; 12(12): 3515-3528.
Liquid biopsy screening based on highly sensitive NGS is reliable for detecting drug resistance and actionable
somatic mutations. The plasma abundance of the EGFR driver mutation affected clinical response to EGFR-TKIs in
advanced NSCLC patients; prolongation of PFS was also observed in patients with an ultra-low abundance of EGFR
Ann Transl Med. 2021 Apr;9(8):635.
if patients are going to undergo TRK-based targeted therapy, only RNA-based NGS for detection of the specific
fusion could tell the precise rearrangement information.
Front Oncol. 2021 Apr 29;11:669197.
BoM was identified as an independent inferior prognostic factor for EGFR-TKI treatment, and may have complex
J Bone Oncol. 2021 May 4;29:100369.
Low TMB level could be the reason for the poor efficacy of ICBs in patients having EGFR mutation. And mutational
frequencies of KRAS and BRCA2 were lower in EGFR-mutant patients. Furthermore, ALK, CDKN2A, MAP2K1, IDH2
and PTEN might involve in the formation of immune phenotypes.
Onco Targets Ther. 2021 May 4;14:2953-2965.